Gene delivery suppresses cancer cell growth and metastasis
Also promotes macrophage engulfment of cancer cells

A research team at Seoul National University Hospital has proposed a gene therapy strategy for triple-negative breast cancer that suppresses cancer cell growth and metastasis while prompting immune cells to attack cancer cells.


Seoul National University Hospital said on Thursday that a research team led by Kim Hyosu of the Biomedical Research Institute and Professor Lee Eunju of the Department of Biomedical Sciences modified the TIF1gamma gene and delivered it to preclinical models of triple-negative breast cancer. The team confirmed that this suppressed cancer cell proliferation and metastasis and enhanced macrophages' ability to engulf cancer cells.


From left: Kim Hyo-soo of Seoul National University Hospital's Biomedical Research Institute, Professor Lee Eun-joo of the Department of Biomedical Sciences, and Dr. Park Hyo-min. Seoul National University Hospital.

From left: Kim Hyo-soo of Seoul National University Hospital's Biomedical Research Institute, Professor Lee Eun-joo of the Department of Biomedical Sciences, and Dr. Park Hyo-min. Seoul National University Hospital.

View original image

Triple-negative breast cancer is a type of breast cancer in which estrogen receptors, progesterone receptors, and HER2 are all absent. It accounts for about 20% of all breast cancers, frequently recurs and metastasizes, and has limited treatment options involving targeted therapies.


The team focused on TIF1gamma, which regulates various cellular signals. Noting that TIF1gamma expression is often reduced in cancer, the researchers developed and tested "opti-hTIF1gamma," optimizing the gene's base sequence so that cells would produce more of the protein.


First, the team delivered the TIF1gamma gene to tumor tissues from seven patients with triple-negative breast cancer whose samples had been obtained at Seoul National University Hospital. As a result, levels of vimentin, which is associated with cancer cell metastasis, and Ki67, a marker of cell proliferation, decreased, while cell death increased. The spread of cancer cells beyond the tissue also fell by about 70%.


Tumor growth was also suppressed in an experiment in which human triple-negative breast cancer cells were transplanted into mice. Tumors in the group treated with the TIF1gamma gene were significantly smaller than those in the control group, and the area occupied by proliferating cancer cells fell to less than 10% of the level in the control group.


The team also confirmed an effect on metastasis. Cancer cells were found in the lymph nodes of the control group but not in those of the treated group. In addition, the lungs of the treated group maintained a normal structure, unlike the cancer lesions found in the lungs of the control group. In another metastasis model, no distinct lung metastases were observed in cancer cells carrying the TIF1gamma gene.


Seoul National University Hospital Presents Multi-Target Gene Therapy Strategy for Triple-Negative Breast Cancer View original image

The team found that TIF1gamma simultaneously suppresses several signals involved in cancer growth and metastasis. TIF1gamma inhibited beta-catenin, which promotes cancer cell growth and migration; TGF-beta, which aids metastasis; and STAT3 signaling, which is involved in cancer cell survival and immune evasion.


Changes were also observed in the immune response. In cancer cells carrying the TIF1gamma gene, levels of CD47, which cancer cells use to evade attacks by immune cells, and CXCL5, which is involved in the recruitment of tumor-promoting macrophages, decreased. Accordingly, expression of SLAMF7, a receptor that promotes the engulfment of cancer cells, increased in macrophages.


In an experiment in which cancer cells and macrophages were cultured together, macrophages engulfed or killed cancer cells carrying the TIF1gamma gene. Cancer cell fragments were also observed inside macrophages in experiments using patient tumor tissue.


The team said the study demonstrates the potential of gene therapy that targets not only cancer cells themselves but also the immune environment surrounding tumors. However, the study is at the preclinical stage. Further development is needed, including technologies that can deliver genes to cancer that has spread throughout the body, before the approach can be used in patients.



Professor Kim Hyosu said, "We confirmed that TIF1gamma alone can simultaneously suppress several signals involved in cancer cell growth and metastasis and restore macrophages' ability to engulf cancer cells. This study demonstrates the potential of multi-target gene therapy that targets both cancer cells and the tumor microenvironment." The findings were published in the latest issue of the international journal Signal Transduction and Targeted Therapy.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing